Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -15.90% is 56% above its 5-year average of -36.41%, near the high end of its 5-year range (-314.42%–-15.90%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.11% above its 12-month average of -22.74%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -15.90%.
RETURN ON EQUITY (ROE)
-15.90%
RETURN ON EQUITY (ROE) AVG TTM
-22.74%
RETURN ON EQUITY (ROE) AVG 3Y
-37.18%
RETURN ON EQUITY (ROE) AVG 5Y
-36.41%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+30.11%
CURRENT VS 3Y AVG
+57.25%
CURRENT VS 5Y AVG
+56.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+62.16%
vs the sector median at left
Trevi Therapeutics, Inc.
Market Cap
$1.87B
Return on Equity (ROE)
-15.90%
TTM Avg
-22.74%
3Y Avg
-37.18%
5Y Avg
-36.41%
Market Cap
$1.86B
Return on Equity (ROE)
N/A
TTM Avg
-157.29%
3Y Avg
-33.70%
5Y Avg
49.06%
Market Cap
$1.89B
Return on Equity (ROE)
12.01%
TTM Avg
-4.52%
3Y Avg
-16.89%
5Y Avg
-11.36%
Market Cap
$1.89B
Return on Equity (ROE)
-186.63%
TTM Avg
-33.22%
3Y Avg
-16.69%
5Y Avg
-32.64%
Market Cap
$1.89B
Return on Equity (ROE)
-40.09%
TTM Avg
4.56%
3Y Avg
-13.84%
5Y Avg
-2.18%
Market Cap
$1.85B
Return on Equity (ROE)
-48.43%
TTM Avg
-97.59%
3Y Avg
-126.46%
5Y Avg
-100.04%
Market Cap
$1.84B
Return on Equity (ROE)
-28.45%
TTM Avg
-88.46%
3Y Avg
-128.76%
5Y Avg
-100.86%
Market Cap
$1.83B
Return on Equity (ROE)
4.88%
TTM Avg
4.47%
3Y Avg
6.79%
5Y Avg
5.89%
Market Cap
$1.83B
Return on Equity (ROE)
-8.95%
TTM Avg
-23.57%
3Y Avg
-73.07%
5Y Avg
-68.36%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | $1.87B | -15.90% | -22.74% | -37.18% | -36.41% |
| Novavax, Inc. (NVAX)vs › | $1.86B | N/A | -157.29% | -33.70% | 49.06% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 12.01% | -4.52% | -16.89% | -11.36% |
| Zymeworks Inc. (ZYME)vs › | $1.89B | -186.63% | -33.22% | -16.69% | -32.64% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -40.09% | 4.56% | -13.84% | -2.18% |
| Immunome, Inc. (IMNM)vs › | $1.85B | -48.43% | -97.59% | -126.46% | -100.04% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | -28.45% | -88.46% | -128.76% | -100.86% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 4.88% | 4.47% | 6.79% | 5.89% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | -8.95% | -23.57% | -73.07% | -68.36% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | -179.99% | -188.10% | 28.98% | -2.67% |
ROE
-15.9%
ROA
-15.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -15.90% |
| 2026-03-31 | -26.50% |
| 2025-12-31 | -23.33% |
| 2025-09-30 | -24.16% |
| 2025-06-30 | -23.83% |
| 2025-03-31 | -47.61% |
| 2024-12-31 | -48.08% |
| 2024-09-30 | -75.15% |
| 2024-06-30 | -58.59% |
| 2024-03-31 | -46.40% |
| 2023-12-31 | -35.21% |
| 2023-09-30 | -29.85% |
| 2023-06-30 | -28.73% |
| 2023-03-31 | -27.74% |
| 2022-12-31 | -27.13% |
| 2022-09-30 | -29.27% |
| 2022-06-30 | -51.48% |
| 2022-03-31 | -314.42% |
| 2021-12-31 | -198.77% |
| 2021-09-30 | -307.06% |
| 2021-06-30 | -197.71% |
| 2021-03-31 | -137.88% |
| 2020-12-31 | -120.07% |
| 2020-09-30 | -83.59% |
| 2020-06-30 | -74.33% |
| 2020-03-31 | -63.50% |
| 2019-12-31 | -47.76% |
| 2019-09-30 | -42.00% |
| 2019-06-30 | -35.13% |
| 2019-03-31 | -168.02% |
| 2018-12-31 | -118.71% |
| 2018-09-30 | -149.85% |
